1Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys,2003,55(1): 110-115.
2Graham MV, Purdy JA, Emami B, et al.Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys, 1999,45(2) : 323-329.
3Armstrong J, Raben A, Zelefsky M, et al.Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol, 1997,44(1): 17-22.
4Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity:a dose-volume histogram analysis in 201patients with lung cancer. Int J Radiat Oncol Biol Phys, 2001,51(3) : 650-659.
5Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in nonsmall-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys,2002,54(2) : 329-339.
6Kim TH, Cho KH, Pyo HR, et al. Dosevolumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology, 2005,235 : 208-215.
7Marks LB, Munley MT, Bentel GC, et al.Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys,1997,39(3): 563-570.
8Lind PA, Marks LB, Hollis D, et al. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys,2002,54(2) : 340-347.
9Byhardt RW, Scott C, Sause WT, et al.Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys,1998,42(3) : 469-478.
10Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage Ⅲ non-small cell lung cancer: a randomized study. J Clin Oncol,1996,14(4): 1065-1070.
9Vander Walde A,Pal SK,Reckamp KL.Management of non-small-cell lung cancer in the older adult[].Maturitas.2011
10Jin Ho Baek, Hawk Kim, Jong - Jong Ahn, et al. Prospective phase Ⅱ trial of a combination of gemcitabine and UFT as first - line treatment in elderly patients with advanced non - small cell lung cancer[ J]. Lung cancer,2012,76:368 - 372.
